PCSK9 and stroke disorder: PCSK9-mAb significantly reduced the risk of stroke (RR 0.75; 95% CI 0.66–0.86, p < 0.0001) and MI (RR 0.81; 95% CI 0.76–0.87, p < 0.00001), but not the risk of cardiovascular death (RR 0.96; 95% CI 0.86–1.07, p = 0.45) compared with placebo [67].